GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to $6.96 billion. The company expects the full year’s revenue to be around $30.2 billion, close to analysts’ estimates. Its non-GAAP profit of $2.03 per share was 6.3% above analysts’ consensus estimates.

Is now the time to buy GILD? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and demand across its core franchises. Management highlighted robust performance in the HIV segment, particularly from Biktarvy and the PrEP portfolio, as well as continued momentum in oncology with Trodelvy and rapid growth from newly launched products like Yes2Go. CEO Daniel O’Day pointed to disciplined financial management and recent product launches as central to the quarter’s performance, while CFO Andrew Dickinson emphasized that non-GAAP operating margins improved due to expense management and the expiration of certain royalties. Notably, management guided to a large negative adjusted EPS for the full year, driven by the impact of acquisition-related IPR&D charges, a key forward-looking disclosure.

Looking ahead, Gilead Sciences’ updated guidance is shaped by anticipated growth in its HIV and oncology portfolios, incremental revenue from recent product launches, and continued pipeline advancements. Management cited increasing contributions from Yes2Go and planned product introductions, but also acknowledged that upfront acquisition costs and integration of recent deals will impact adjusted EPS for the year, with full-year non-GAAP EPS guidance in a loss range due to these charges. O’Day stated, “We are focused on executing our expanding pipeline and integrating new assets, which positions us for both near-term launches and long-term growth.”

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to new HIV prevention therapies, strong oncology demand, and operational discipline, while recent acquisitions and clinical development set the stage for future growth.

• HIV portfolio expansion: The HIV business saw 10% year-over-year growth, led by Biktarvy and an 87% surge in the U.S. PrEP segment, driven by the successful launch and rapid uptake of Yes2Go, the company’s twice-yearly injectable for HIV prevention.
• Oncology momentum: Trodelvy sales increased 37% year-over-year, benefiting from growing demand in metastatic triple-negative breast cancer and support from updated clinical guidelines, which management said could pave the way for broader first-line use.
• Libdelzi launches in liver disease: The liver franchise was highlighted by Libdelzi’s strong performance in second-line primary biliary cholangitis, with sales more than tripling year-over-year and rapid prescriber adoption in the U.S. and Europe. Sequentially, however, Libdelzi sales declined by 11% due to inventory drawdown and the normalization after a Q4 bolus, as noted by management.
• Recent acquisitions strengthen pipeline: The completed acquisition of Arcellx and pending deals for Oral Medicines and Tubulis added novel clinical assets in oncology and inflammation. Management believes these moves lay the groundwork for multiple new launches and a more diversified revenue base.
• Margin enhancement from expense control: Operating margin expansion was attributed to the expiration of royalty obligations and ongoing cost management, helping to offset higher selling expenses and integration costs from recent transactions. Importantly, management specified that the 47% non-GAAP operating margin excludes one-time charges, while the GAAP margin is much lower due to acquisition-related costs.

Drivers of Future Performance

Gilead Sciences’ full-year outlook is shaped by HIV franchise growth, new product launches, and integration of recent acquisitions, while increased R&D and transaction costs will weigh on profit margins. Management has guided to a significant negative non-GAAP EPS for the year due to large upfront payments relating to recent acquisitions.

• HIV and prevention uptake: Management expects continued strong growth in HIV treatment and prevention, supported by increasing adoption of Yes2Go and the anticipated launch of Biclen, a once-daily oral regimen for virally suppressed people with HIV. The company aims to maintain leadership as up to seven new HIV products could launch by 2033, though policy-driven pricing headwinds are expected to modestly offset gains.
• Oncology and cell therapy launches: Upcoming regulatory decisions for Trodelvy and new assets from Tubulis and Arcellx are projected to expand Gilead’s position in oncology, with management highlighting differentiated candidates for ovarian cancer and multiple myeloma. Revenue contributions are expected to ramp in 2027 and beyond as pipeline assets progress through pivotal studies and approvals.
• Cost structure and integration risks: The integration of new acquisitions and associated R&D investment will increase operating expenses and impact adjusted earnings per share in the near term. Management stated that excluding acquisition-related upfront payments, the underlying business remains on track, but warned that successful clinical execution and market access for new therapies are critical to achieving long-term targets. Full-year non-GAAP EPS is expected to be in a loss range due to these acquisition-related charges.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will be closely monitoring (1) regulatory decisions for key products like Biclen in HIV and Trodelvy in breast cancer, (2) the pace of integration and progress for newly acquired assets from Arcellx, Tubulis, and Oral Medicines, and (3) continued uptake of Yes2Go and Libdelzi in their respective markets. The timing of pivotal clinical trial readouts and product launches will also be critical in assessing execution on Gilead Sciences’ growth strategy.

Gilead Sciences currently trades at $132.47, down from $134.25 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.